LIVIVO - Search results -

Search results

Result 1 - 10 of total 157

Search options

Article ; Online: Biologics in COPD.

Kersul, Ana L / Cosio, Borja G

Open respiratory archives

2024 Volume 6, Issue 2, Page(s) 100306

Language	English
Publishing date	2024-02-15
Publishing country	Spain
Document type	Editorial
ISSN	2659-6636
ISSN (online)	2659-6636
DOI	10.1016/j.opresp.2024.100306
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Impact of comorbidities in COPD clinical control criteria. The CLAVE study.

Almagro, Pere / Soler-Cataluña, Juan José / Huerta, Arturo / González-Segura, Diego / Cosío, Borja G

BMC pulmonary medicine

2024 Volume 24, Issue 1, Page(s) 6

Abstract: Background: Chronic obstructive pulmonary disease (COPD) frequently coexists with other chronic diseases, namely comorbidities. They negatively impact prognosis, exacerbations and quality of life in COPD patients. However, no studies have been performed ...

Abstract	Background: Chronic obstructive pulmonary disease (COPD) frequently coexists with other chronic diseases, namely comorbidities. They negatively impact prognosis, exacerbations and quality of life in COPD patients. However, no studies have been performed to explore the impact of these comorbidities on COPD clinical control criteria. Research question: Determine the relationship between individualized comorbidities and COPD clinical control criteria. Study design and methods: Observational, multicenter, cross-sectional study performed in Spain involving 4801 patients with severe COPD (< 50 predicted forced expiratory volume in the first second [FEV Results: Most frequent comorbidities were arterial hypertension (51.2%), dyslipidemia (36.0%), diabetes (24.9%), obstructive sleep apnea-hypopnea syndrome (14.9%), anxiety (14.1%), heart failure (11.6%), depression (11.8%), atrial fibrillation (11.5%), peripheral arterial vascular disease (10.4%) and ischemic heart disease (10.1%). After age and FEV Interpretation: Comorbidities are frequent in patients with severe COPD, negatively impacting COPD clinical control criteria. They are related to health-related quality of life measured by the COPD assessment test. Our results suggest that comorbidities should be investigated and treated in these patients to improve their clinical control. Take-home points: Study question: What is the impact of comorbidities on COPD clinical control criteria? Results: Among 4801 patients with severe COPD (27.5% controlled and 72.5% uncontrolled), after adjustment by age and FEV Interpretation: Comorbidities are related to health-related quality of life measured by the COPD assessment test scores and history of exacerbations in the previous three months.
MeSH term(s)	Humans ; Atrial Fibrillation ; Cross-Sectional Studies ; Diabetes Mellitus ; Forced Expiratory Volume ; Gastroesophageal Reflux/epidemiology ; Gastroesophageal Reflux/complications ; Heart Failure ; Hypertension/complications ; Obesity, Abdominal/complications ; Peripheral Vascular Diseases/complications ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Quality of Life ; Sleep Apnea, Obstructive/complications
Language	English
Publishing date	2024-01-02
Publishing country	England
Document type	Multicenter Study ; Journal Article
ZDB-ID	2059871-3
ISSN	1471-2466 ; 1471-2466
ISSN (online)	1471-2466
ISSN	1471-2466
DOI	10.1186/s12890-023-02758-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Is it Time to Readjust the Doses of Inhaled Corticosteroids in COPD?

Cosío, Borja G / Shafiek, Hanaa / Martínez-García, Miguel Ángel

Archivos de bronconeumologia

2022 Volume 58, Issue 8, Page(s) 593–594

MeSH term(s)	Administration, Inhalation ; Adrenal Cortex Hormones/therapeutic use ; Humans ; Pulmonary Disease, Chronic Obstructive/drug therapy
Chemical Substances	Adrenal Cortex Hormones
Language	Spanish
Publishing date	2022-02-13
Publishing country	Spain
Document type	Editorial
ZDB-ID	733126-5
ISSN	1579-2129 ; 0300-2896
ISSN (online)	1579-2129
ISSN	0300-2896
DOI	10.1016/j.arbres.2022.01.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2655: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy.

Riera-Martínez, Lluc / Cànaves-Gómez, Laura / Iglesias, Amanda / Martin-Medina, Aina / Cosío, Borja G

International journal of molecular sciences

2023 Volume 24, Issue 10

Abstract: COPD is a leading cause of mortality and morbidity worldwide and is associated with a high socioeconomic burden. Current treatment includes the use of inhaled corticosteroids and bronchodilators, which can help to improve symptoms and reduce ... ...

Abstract	COPD is a leading cause of mortality and morbidity worldwide and is associated with a high socioeconomic burden. Current treatment includes the use of inhaled corticosteroids and bronchodilators, which can help to improve symptoms and reduce exacerbations; however, there is no solution for restoring lung function and the emphysema caused by loss of the alveolar tissue. Moreover, exacerbations accelerate progression and challenge even more the management of COPD. Mechanisms of inflammation in COPD have been investigated over the past years, thus opening new avenues to develop novel targeted-directed therapies. Special attention has been paid to IL-33 and its receptor ST2, as they have been found to mediate immune responses and alveolar damage, and their expression is upregulated in COPD patients, which correlates with disease progression. Here we summarize the current knowledge on the IL-33/ST2 pathway and its involvement in COPD, with a special focus on developed antibodies and the ongoing clinical trials using anti-IL-33 and anti-ST2 strategies in COPD patients.
MeSH term(s)	Humans ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Adrenal Cortex Hormones/therapeutic use ; Bronchodilator Agents/therapeutic use ; Pulmonary Emphysema/drug therapy ; Emphysema ; Disease Progression
Chemical Substances	Adrenal Cortex Hormones ; Bronchodilator Agents
Language	English
Publishing date	2023-05-12
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24108702
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option.

Soler-Cataluña, Juan José / Huerta, Arturo / Almagro, Pere / González-Segura, Diego / Cosío, Borja G

International journal of chronic obstructive pulmonary disease

2023 Volume 18, Page(s) 1367–1376

Abstract: Introduction: According to the Global Initiative for chronic obstructive lung disease (GOLD), when a treatment is not achieving an appropriate response it should be switched taking into account the predominant treatable trait to target (dyspnea or ... ...

Abstract	Introduction: According to the Global Initiative for chronic obstructive lung disease (GOLD), when a treatment is not achieving an appropriate response it should be switched taking into account the predominant treatable trait to target (dyspnea or exacerbations). The objective of the present study was to investigate the lack of clinical control according to the target and medication groups. Materials and methods: This was a post-hoc analysis of the CLAVE study, an observational, cross-sectional, multicenter study which evaluated the clinical control, and related-factors, in a cohort of 4801 patients with severe chronic obstructive pulmonary disease (COPD). The primary endpoint was the percentage of uncontrolled patients defined as COPD Assessment Test (CAT) >16 or presence of exacerbations in the last 3 months despite receiving long-acting beta Results: In the dyspnea pathway, lack of clinical control was of 25.0% of patients receiving LABA or LAMA in monotherapy, 29.5% by those with LABA + LAMA, 38.3% with LABA + ICS and 37.0% with triple therapy (LABA + LAMA + ICS). In the exacerbation pathway, percentages were 87.1%, 76.7%, 83.3%, and 84.1%, respectively. Low physical activity and high Charlson comorbidity index were independent factor of non-control in all therapeutic groups. Additional factors were lower post-bronchodilator FEV1 and poor adherence to inhalers. Conclusion: There are still room for improvement in COPD control. From the pharmacological perspective, every step in treatment have a pool of uncontrolled patients in which a step-up could be considered according to a trait to target strategy.
MeSH term(s)	Humans ; Cross-Sectional Studies ; Dyspnea ; Exercise ; Muscarinic Antagonists ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/drug therapy
Chemical Substances	Muscarinic Antagonists
Language	English
Publishing date	2023-07-06
Publishing country	New Zealand
Document type	Observational Study ; Multicenter Study ; Journal Article
ZDB-ID	2212419-6
ISSN	1178-2005 ; 1176-9106
ISSN (online)	1178-2005
ISSN	1176-9106
DOI	10.2147/COPD.S414910
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The dose of inhaled corticosteroids in patients with COPD: when less is better.

Izquierdo, José Luis / Cosio, Borja G

International journal of chronic obstructive pulmonary disease

2018 Volume 13, Page(s) 3539–3547

Abstract: Background: The use of inhaled corticosteroids (ICS) in combination with bronchodilators in patients with COPD has been shown to decrease the rate of disease exacerbations and to improve the lung function and patients' quality of life. However, their ... ...

Abstract	Background: The use of inhaled corticosteroids (ICS) in combination with bronchodilators in patients with COPD has been shown to decrease the rate of disease exacerbations and to improve the lung function and patients' quality of life. However, their use has also been associated with an increased risk of pneumonia. Materials and methods: We have reviewed existing clinical evidence on the risks and benefits of ICS in COPD, including large randomized clinical trials, meta-analyses, and clinical reviews. Results: A large body of evidence supports the clinical benefits of ICS in patients with COPD in terms of exacerbations, symptoms, lung function, and quality of life. The incidence of adverse events related to ICS, including pneumonia, varies strongly among the studies and seems to be dose dependent, with recent well-designed, large studies on low-dose ICS reporting similar safety profiles in ICS and non-ICS groups. Conclusion: The benefits of ICS in COPD continue to outweigh the risks, especially when lower ICS doses are employed. Given that the data on ICS withdrawal in COPD are scarce and conflicting, we argue that using reduced doses of ICS could be an optimal strategy to manage patients with COPD.
MeSH term(s)	Administration, Inhalation ; Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; Dose-Response Relationship, Drug ; Humans ; Incidence ; Lung/drug effects ; Lung/physiopathology ; Pneumonia/chemically induced ; Pneumonia/epidemiology ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quality of Life ; Recovery of Function ; Risk Factors ; Treatment Outcome
Chemical Substances	Adrenal Cortex Hormones
Language	English
Publishing date	2018-10-25
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2212419-6
ISSN	1178-2005 ; 1176-9106
ISSN (online)	1178-2005
ISSN	1176-9106
DOI	10.2147/COPD.S175047
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach.

Quirce, Santiago / Cosío, Borja G / España, Agustín / Blanco, Ricardo / Mullol, Joaquim / Santander, Cecilio / Del Pozo, Victoria

Frontiers in immunology

2023 Volume 14, Page(s) 1192284

Abstract: Elevated eosinophil counts in blood and tissue are a feature of many pathological processes. Eosinophils can migrate and accumulate in a wide variety of tissues and, by infiltrating a target organ, can mediate the development of several inflammatory ... ...

Abstract	Elevated eosinophil counts in blood and tissue are a feature of many pathological processes. Eosinophils can migrate and accumulate in a wide variety of tissues and, by infiltrating a target organ, can mediate the development of several inflammatory diseases. The normalization of eosinophilia is a common biomarker of a treatable trait and can also be used as a prognostic and predictive biomarker since it implies a reduction in type 2 inflammation that contributes to disease pathogenesis. Biological therapies targeting this cell type and its proinflammatory mediators have been shown to be effective in the management of a number of eosinophilic diseases, and for this reason they constitute a potential common strategy in the treatment of patients with various multimorbidities that present with type 2 inflammation. Various biological options are available that could be used to simultaneously treat multiple target organs with a single drug, bearing in mind the need to offer personalized treatments under the umbrella of precision medicine in all patients with eosinophil-associated diseases (EADs). In addition to reviewing these issues, we also discuss a series of perspectives addressing the management of EAD patients from a multidisciplinary approach, with the collaboration of health professionals from different specialties who manage the different multimorbidities that frequently occur in these patients. We examine the basic principles of care that this multidisciplinary approach must cover and present a multidisciplinary expert opinion regarding the ideal management of patients with EADs, from diagnosis to therapeutic approach and follow-up.
MeSH term(s)	Humans ; Eosinophils/metabolism ; Eosinophilia/pathology ; Inflammation/therapy ; Inflammation/pathology ; Biomarkers
Chemical Substances	Biomarkers
Language	English
Publishing date	2023-05-17
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2023.1192284
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study.

Soler-Cataluña, Juan José / Almagro, Pere / Huerta, Arturo / González-Segura, Diego / Cosío, Borja G

International journal of chronic obstructive pulmonary disease

2021 Volume 16, Page(s) 137–146

Abstract: Background: Clinical control in chronic obstructive pulmonary disease (COPD) has not been completely characterized. A proposal of clinical control criteria (CCC) has been recently defined and validated as a tool for determining control, but there is ... ...

Abstract	Background: Clinical control in chronic obstructive pulmonary disease (COPD) has not been completely characterized. A proposal of clinical control criteria (CCC) has been recently defined and validated as a tool for determining control, but there is scarce information on patients with severe COPD. Objective: To evaluate clinical control in severe COPD using the CCC. Patients and methods: The study design was observational, multicenter, cross-sectional study involving 4801 patients with severe COPD in Spain. Clinical control was defined according to clinical impact (dyspnea grade, use of rescue treatment in last week, sputum color, and daily physical activity) and stability (exacerbations in last 3 months and patient's perception about health status). Clinical control of COPD was alternatively evaluated with the COPD assessment test (CAT) and the presence of exacerbations in the last 3 months. Results: According to CCC, 61.0% of patients had low clinical impact, and 41.4% showed clinical stability. Overall, 29.9% of patients had both low clinical impact and stability (controlled), whereas 70.1% showed high clinical impact and/or no clinical stability (non-controlled). COPD control was also assessed by using only the definition of CAT≤16 and no exacerbations in the last 3 months. Results obtained with this definition were similar to those obtained by CCC, and the concordance between both definitions was high (Kappa index = 0.698). Conclusion: By using the CCC, approximately only one third of patients with severe COPD were considered as controlled. Physical activity, adherence to inhalers, age, post-bronchodilator FEV
MeSH term(s)	Cross-Sectional Studies ; Disease Progression ; Dyspnea ; Humans ; Lung ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Pulmonary Disease, Chronic Obstructive/therapy ; Spain/epidemiology
Language	English
Publishing date	2021-01-25
Publishing country	New Zealand
Document type	Journal Article ; Multicenter Study ; Observational Study
ZDB-ID	2212419-6
ISSN	1178-2005 ; 1176-9106
ISSN (online)	1178-2005
ISSN	1176-9106
DOI	10.2147/COPD.S285385
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: What is early COPD and why is it important?

Soriano, Joan B / Polverino, Francesca / Cosio, Borja G

The European respiratory journal

2018 Volume 52, Issue 6

Abstract: There is increasing interest in the origins of chronic obstructive pulmonary disease (COPD), as it is envisaged that preventive efforts and treatment can modify its clinical course. The concept of early COPD is not new, but it has recently regained ... ...

Abstract	There is increasing interest in the origins of chronic obstructive pulmonary disease (COPD), as it is envisaged that preventive efforts and treatment can modify its clinical course. The concept of early COPD is not new, but it has recently regained interest, given new population data, recent cellular and molecular advances and insights from clinical trials. To date, many knowledge gaps in the nature of early COPD still exist, mainly because COPD has always been considered a disease of the elderly, and little attention has been paid to the pathological changes occurring in the lungs of individuals at risk before they develop clinically evident COPD. Future studies should focus on identifying early pathological manifestations of COPD in order to prevent its progression in susceptible individuals. In this review, we aim to summarise what is known on early COPD, from the epidemiological, cellular and clinical perspectives.
MeSH term(s)	Age of Onset ; Disease Progression ; Humans ; Lung/physiopathology ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Risk Factors
Language	English
Publishing date	2018-12-06
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	639359-7
ISSN	1399-3003 ; 0903-1936
ISSN (online)	1399-3003
ISSN	0903-1936
DOI	10.1183/13993003.01448-2018
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2322: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 292: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: COPD: systemic proteomic profiles in frequent and infrequent exacerbators.

Enríquez-Rodríguez, Cesar Jessé / Casadevall, Carme / Faner, Rosa / Castro-Costa, Ady / Pascual-Guàrdia, Sergi / Seijó, Luis / López-Campos, José Luis / Peces-Barba, Germán / Monsó, Eduard / Barreiro, Esther / Cosío, Borja G / Agustí, Alvar / Gea, Joaquim

ERJ open research

2024 Volume 10, Issue 2

Abstract: Background: Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE). The objective of the present study was to contrast the ... ...

Abstract	Background: Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE). The objective of the present study was to contrast the systemic proteomic profile in FE Methods: In the analysis we included 40 clinically stable COPD patients (20 FE and 20 NFE), and 20 HC and 10 AE patients. Their plasma samples were analysed by combining two complementary proteomic approaches: label-free liquid chromatography-tandem mass spectrometry and multiplex immunoassays. Gene Ontology annotation, pathway enrichment and network analyses were used to investigate molecular pathways associated with differentially abundant proteins/peptides (DAPs). Results: Compared with HC, we identified 40 DAPs in FE, 10 in NFE and 63 in AE. Also compared to HC, pathway functional and protein-protein network analyses revealed dysregulation of inflammatory responses involving innate and antibody-mediated immunity in COPD, particularly in the FE group, as well as during an AE episode. Besides, we only identified alterations in the complement and coagulation cascades in AE. Conclusion: There are specific plasma proteome profiles associated with FE, which are partially shared with findings observed during AE, albeit others are uniquely present during the actual episode of AE.
Language	English
Publishing date	2024-03-25
Publishing country	England
Document type	Journal Article
ZDB-ID	2827830-6
ISSN	2312-0541
ISSN	2312-0541
DOI	10.1183/23120541.00004-2024
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Your last searches

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito